基金简介

introduction

Fosun Health Capital, the first VC fund established by Fosun Pharma, aiming to invest in innovative drug products and technologies with rapid growth potential at the initial and expansion phases, making full use of our connections with six oversea cooperative VCs, to source world-class and high-quality technologies and products for China markets.
 
Fosun Health Capital was established in August 2020 with its first fund of RMB 1.5 billion and was fully closed in February 2021. The fund will promote the innovation for biotech industry withstrong support from government and Fosun Pharma, helping the portfolio companies to develop rapidly in their fields.

 

INVESTMENT FIELD

Investment field

Gene therapy

to deliver target genes through a variety of innovative vectors to treat diseases caused by defective and abnormal genes, therefore achieving long-term remission or even full recovery.

Cell therapy

to track the cutting-edge progress of autologous & allogeneic cell therapy for the treatment of tumors, metabolic abnormalities, aging, etc.

New biological entities (NBEs)

to explore cooperation opportunities with new entities such as bispecific antibodies, ADCs, nucleic acid medicine, etc. and expand horizons in drug discovery & design to create the next blockbuster.

投资人

investors